Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kieren Mather

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
The Canadian Journal of Cardiology|August 17, 2004
Insulin resistance, metabolic syndrome and vascular diseases: update on mechanistic linkagesAmale Lteif, Kieren Mather
Arteriosclerosis, Thrombosis, and Vascular Biology|August 17, 2012
Targeting the consequences of the metabolic syndrome in the Diabetes Prevention ProgramRonald B Goldberg, Kieren Mather
Current Drug Targets. Cardiovascular & Haematological Disorders|March 23, 2004
Insulin resistance as a therapeutic target for improved endothelial function: metforminLori Brame, Subodh Verma, Todd Anderson, et al.
Diabetes, Obesity & Metabolism|March 4, 2022
Type 2 diabetes pharmacotherapy trends in high-risk subgroupsJay Bae, Dongju Liu, Chanadda Chinthammit, et al.
Cardiovascular Diabetology|June 6, 2025
Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetesSean Wharton, Julio Rosenstock, Manige Konige, et al.
Healthcare (Basel, Switzerland)|August 14, 2025
A Post-Hoc Analysis of Depressive Disorders in Patients with Type 2 DiabetesYegan Pillay, W Guyton Hornsby, Chandan K Saha, et al.
BMJ Open Diabetes Research & Care|October 31, 2017
Statin use and risk of developing diabetes: results from the Diabetes Prevention ProgramJill P Crandall, Kieren Mather, Swapnil N Rajpathak, et al.
Diabetes|April 28, 2005
Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose toleranceSteven Haffner, Marinella Temprosa, Jill Crandall, et al.
Metabolism: Clinical and Experimental|April 18, 2016
Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention ProgramRonald B Goldberg, Marinella Temprosa, Lisa Mele, et al.
Diabetes Care|July 4, 2012
The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention ProgramJose C Florez, Kathleen A Jablonski, Andrew Taylor, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
The Canadian Journal of Cardiology|August 17, 2004
Insulin resistance, metabolic syndrome and vascular diseases: update on mechanistic linkagesAmale Lteif, Kieren Mather
Arteriosclerosis, Thrombosis, and Vascular Biology|August 17, 2012
Targeting the consequences of the metabolic syndrome in the Diabetes Prevention ProgramRonald B Goldberg, Kieren Mather
Current Drug Targets. Cardiovascular & Haematological Disorders|March 23, 2004
Insulin resistance as a therapeutic target for improved endothelial function: metforminLori Brame, Subodh Verma, Todd Anderson, et al.
Diabetes, Obesity & Metabolism|March 4, 2022
Type 2 diabetes pharmacotherapy trends in high-risk subgroupsJay Bae, Dongju Liu, Chanadda Chinthammit, et al.
Cardiovascular Diabetology|June 6, 2025
Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetesSean Wharton, Julio Rosenstock, Manige Konige, et al.
Healthcare (Basel, Switzerland)|August 14, 2025
A Post-Hoc Analysis of Depressive Disorders in Patients with Type 2 DiabetesYegan Pillay, W Guyton Hornsby, Chandan K Saha, et al.
BMJ Open Diabetes Research & Care|October 31, 2017
Statin use and risk of developing diabetes: results from the Diabetes Prevention ProgramJill P Crandall, Kieren Mather, Swapnil N Rajpathak, et al.
Diabetes|April 28, 2005
Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose toleranceSteven Haffner, Marinella Temprosa, Jill Crandall, et al.
Metabolism: Clinical and Experimental|April 18, 2016
Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention ProgramRonald B Goldberg, Marinella Temprosa, Lisa Mele, et al.
Diabetes Care|July 4, 2012
The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention ProgramJose C Florez, Kathleen A Jablonski, Andrew Taylor, et al.
Pageof 2